Ingrid Tonning Olsson

Dr. Ingrid Tonning Olsson

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Pediatric Neurology
Verified
Journal Article
Closed access
IOIngrid Tonning Olsson
Ingrid Tonning Olsson
SPSean Perrin
Sean Perrin
JLJohan Lundgren
Johan Lundgren
LHLars Hjorth
Lars Hjorth
AJAki Johanson
Aki Johanson

20 September 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TBTara M. Brinkman
Tara M. Brinkman
KNKirsten K. Ness
Kirsten K. Ness
ZLZhenghong Li
Zhenghong Li
IHI-Chan Huang
I-Chan Huang
KKKevin R. Krull
Kevin R. Krull
GAGregory T. Armstrong
Gregory T. Armstrong
Purpose: Beyond survival, achieving independence is a primary goal for adult survivors of pediatric CNS tumors. However, the prevalence of and risk factors for failure to achieve independence, assessed with multiple concurrent indicators, have not been examined. Patients and Methods: Functional and social independence was assessed in 306 survivors (astrocytoma [n = 130], medulloblastoma [n = 77], ependymoma [n = 36], and other [n = 63]; median current age, 25.3 years [range, 18.9 to 53.1 years]; time since diagnosis, 16.8 years [range, 10.6 to 41.8 years]). Six observed indicators were used to identify latent classes of independence, which included employment, living independently, assistance with personal care, assistance with routine needs, obtaining a driver’s license, and marital status. Physical performance impairments were defined as scores < 10th percentile on measures of aerobic capacity, strength, flexibility, balance, mobility, and adaptive function. Multinomial logistic regression estimated odds ratios (ORs) and 95% CIs were calculated for associations of disease/treatment exposures and impairments in physical performance with nonindependence. Results: Three classes of independence were identified as independent (40%), moderately independent (34%), and nonindependent (26%). In multivariable models, craniospinal irradiation (OR, 4.20; 95% CI, 1.69 to 10.44) and younger age at diagnosis (OR, 1.24; 95% CI, 1.14 to 1.35) were associated with risk of nonindependence versus independence. Beyond impaired IQ, limitations in aerobic capacity (OR, 5.47; 95% CI, 1.78 to 16.76), flexibility (OR, 3.66; 95% CI, 1.11 to 12.03), and adaptive physical function (OR, 11.54; 95% CI, 3.57 to 37.27) were associated with nonindependence versus independence. Nonindependent survivors reported reduced physical but not mental health-related quality of life compared with independent survivors. Conclusion: Sixty percent of survivors of pediatric CNS tumors do not achieve complete independence as adults. Reduction in intensity of primary therapies and interventions that target physical performance and adaptive deficits may help survivors to achieve greater independence.

21 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MWMorten Wibroe
Morten Wibroe
JCJohan Cappelen
Johan Cappelen
Charlotte CastorCharlotte Castor
Charlotte Castor
NCNiels Clausen
Niels Clausen
PGPernilla Grillner
Pernilla Grillner
MJMarianne Juhler
Marianne Juhler
Central nervous system tumours constitute 25% of all childhood cancers; more than half are located in the posterior fossa and surgery is usually part of therapy. One of the most disabling late effects of posterior fossa tumour surgery is the cerebellar mutism syndrome (CMS) which has been reported in up to 39% of the patients but the exact incidence is uncertain since milder cases may be unrecognized. Recovery is usually incomplete. Reported risk factors are tumour type, midline location and brainstem involvement, but the exact aetiology, surgical and other risk factors, the clinical course and strategies for prevention and treatment are yet to be determined. This observational, prospective, multicentre study will include 500 children with posterior fossa tumours. It opened late 2014 with participation from 20 Nordic and Baltic centres. From 2016, five British centres and four Dutch centres will join with a total annual accrual of 130 patients. Three other major European centres are invited to join from 2016/17. Follow-up will run for 12 months after inclusion of the last patient. All patients are treated according to local practice. Clinical data are collected through standardized online registration at pre-determined time points pre- and postoperatively. Neurological status and speech functions are examined pre-operatively and postoperatively at 1–4 weeks, 2 and 12 months. Pre- and postoperative speech samples are recorded and analysed. Imaging will be reviewed centrally. Pathology is classified according to the 2007 WHO system. Germline DNA will be collected from all patients for associations between CMS characteristics and host genome variants including pathway profiles. Through prospective and detailed collection of information on 1) differences in incidence and clinical course of CMS for different patient and tumour characteristics, 2) standardized surgical data and their association with CMS, 3) diversities and results of other therapeutic interventions, and 4) the role of host genome variants, we aim to achieve a better understanding of risk factors for and the clinical course of CMS - with the ultimate goal of defining strategies for prevention and treatment of this severely disabling condition. Clinicaltrials.gov : NCT02300766 , date of registration: November 21, 2014.

8 September 2018 in Addiction
Verified
Journal Article
Closed access
PDF file
TBTara M Brinkman
Tara M Brinkman
ELE. Anne Lown
E. Anne Lown
CLChenghong Li
Chenghong Li
IOIngrid Tonning Olsson
Ingrid Tonning Olsson
JMJordan Gilleland Marchak
Jordan Gilleland Marchak
KKKevin R. Krull
Kevin R. Krull

26 June 2019 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
IOIngrid Tonning Olsson
Ingrid Tonning Olsson
TBTara M. Brinkman
Tara M. Brinkman
GHGeehong Hyun
Geehong Hyun
PBPia Banerjee
Pia Banerjee
DMDaniel A. Mulrooney
Daniel A. Mulrooney
Kevin KrullKevin Krull
Kevin Krull

19 February 2020 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
IOIngrid Tonning Olsson
Ingrid Tonning Olsson
MLMargaret M Lubas
Margaret M Lubas
CLChenghong Li
Chenghong Li
BMBelinda N Mandrell
Belinda N Mandrell
PBPia Banerjee
Pia Banerjee
TBTara M Brinkman
Tara M Brinkman
In noncancer populations, insomnia is known to affect neurocognitive processes. Although the prevalence of insomnia appears to be elevated in survivors of childhood cancer, relatively little is known about its association with neurocognitive performance in this at-risk population. A total of 911 survivors (51.9% female; mean [SD] age, 34 [9.0] years; time since diagnosis, 26 [9.1] years) completed direct assessments of attention, memory, processing speed, and executive functioning and self-reported symptoms of sleep (Pittsburgh Sleep Quality Index), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue), and daytime sleepiness (Epworth Sleepiness Scale). Sex-stratified general linear models were used to examine associations between insomnia and neurocognitive performance, with adjustment for treatment exposures and chronic health conditions. All statistical tests were two-sided. Insomnia was reported by 22.1% of females and 12.3% of males (P < .001). After adjustment for neurotoxic treatment exposures, insomnia (vs healthy sleepers with no daytime fatigue or sleepiness) was associated with worse neurocognitive performance in the domains of verbal reasoning, memory, attention, executive function, and processing speed (verbal reasoning: males β = −0.34, P = .04, females β = −0.57, P < .001; long-term memory: males β = −0.60, P < .001, females β = −0.36, P = .02; sustained attention: males β = −0.85, P < .001, females β = −0.42, P = .006; cognitive flexibility: males β = −0.70, P = .002, females β = −0.40, P = .02). Self-reported sleep disturbance without daytime fatigue or sleepiness or daytime fatigue or sleepiness alone were not consistently associated with poorer neurocognitive performance. Insomnia was highly prevalent and contributed to the neurocognitive burden experienced by adult survivors of childhood cancer. Treatment of insomnia may improve neurocognitive problems in survivors.